---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-097449"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:25:01.514663+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports Q3 2024 product sales up 11% to $6M; net loss narrows to $702k

## Summary
- Product sales $6M in Q3 2024 vs $5.4M in Q3 2023 (+11%); 9-month sales $18.7M (+51% YoY).
- Net loss $702k ($0.09/sh) vs $940k ($0.12/sh) in Q3 2023; 9-month loss $2.7M vs $4.6M.
- Gross margin improved to 26% of sales in Q3 2024 from 23% in Q3 2023.
- EBITDA turned positive to ~$119k in Q3 2024 from ($95k) in Q3 2023.
- Cash increased to $3.8M from $979K at Dec 31, 2023; no line of credit drawn.

## SEC filing metadata
- accession: 0001213900-24-097449
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024097449/0001213900-24-097449-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024097449/ea0221098-8k_immu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-097449
- JSON: https://secwatch.observer/filing/0001213900-24-097449.json
- Plain text: https://secwatch.observer/filing/0001213900-24-097449.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.